eCite Digital Repository

Levofloxacin: Insights into antibiotic resistance and product quality

Citation

Izadi, E and Afshan, G and Patel, RP and Rao, V and Liew, KB and Affandi, MMRMM and Kifli, N and Suleiman, A and Lee, KS and Sarker, MMR and Zaidi, ST and Ming, LC, Levofloxacin: Insights into antibiotic resistance and product quality, Frontiers in Pharmacology, 10 pp. 1-7. ISSN 1663-9812 (2019) [Refereed Article]


Preview
PDF
Not available
881Kb
  

DOI: doi:10.3389/fphar.2019.00881

Abstract

Counterfeit and substandard medicines are recognized as one of serious threats to public health. The product quality of antibacterial medicine will compromise patients' recovery and increase the chance of antibacterial resistance. The review aims to provide a summary of low quality levofloxacin issues and the risk factors as well as suggesting the aspects of product quality that need to be regulated strictly. Quality of the active ingredient, levofloxacin, has an important role to contribute to successful therapy. The poor quality of raw material, directly and indirectly, causes treatment failure as the presence of insufficient dose, mislabeled content, and poor dissolution characteristics can lead to lower bioavailability. Identifying and reporting these factors can potentially help in improving the quality of drug marketed in various developing countries and may also reduce the incidences of treatment failure. Dissolution test is used for testing the dissolution profiles and the rate of drug release from solid formulation such as oral formulations, thus providing information regarding the in vivo performance of a formulation and its bioequivalence. On the other hand, quality-testing procedures are used for comparing the quality of products.

Item Details

Item Type:Refereed Article
Keywords:counterfeit, post marketing surveillance, regulatory requirement, fluroquinolone resistance, quality medicine
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Izadi, E (Ms Ensieh Izadi)
UTAS Author:Patel, RP (Dr Rahul Patel)
UTAS Author:Zaidi, ST (Dr Tabish Razi Zaidi)
UTAS Author:Ming, LC (Dr Long Ming)
ID Code:151638
Year Published:2019
Web of Science® Times Cited:10
Deposited By:Pharmacy
Deposited On:2022-08-02
Last Modified:2022-08-02
Downloads:0

Repository Staff Only: item control page